Ravi S Talluri

Title: Innovations in Ocular Treatment by Ravi S Talluri

Introduction

Ravi S Talluri is an accomplished inventor based in Kansas City, MO (US). He has made significant contributions to the field of ocular treatment through his innovative research and patented inventions. His work focuses on enhancing the delivery of antiviral agents to ocular tissues, which is crucial for effective treatment.

Latest Patents

Ravi S Talluri holds a patent for "Stereochemically defined dipeptide esters of antiviral agents for enhanced ocular treatment." This patent involves stereochemically defined dipeptide esters of nucleoside-analogous antiviral agents, including acyclovir and ganciclovir. These compounds have been found to cross the blood-ocular barrier more effectively than other similar compounds, leading to improved delivery and uptake by ocular tissues. For instance, the compound (L-Val)-(D-Val)-acyclovir demonstrated superior uptake into corneal tissue compared to underivatized acyclovir and other monoesters or diesters.

Career Highlights

Ravi S Talluri is affiliated with the University of Missouri, where he conducts his research and development. His work has garnered attention for its potential to revolutionize ocular treatments, particularly for viral infections affecting the eye. With a focus on enhancing therapeutic efficacy, Talluri's contributions are paving the way for more effective ocular therapies.

Collaborations

Ravi has collaborated with notable colleagues such as Ashim K Mitra and Swapan Kumar Samanta. These collaborations have enriched his research and expanded the impact of his innovations in the field of ocular medicine.

Conclusion

Ravi S Talluri's innovative work in developing stereochemically defined dipeptide esters represents a significant advancement in ocular treatment. His contributions are vital for improving the effectiveness of antiviral therapies, ultimately benefiting patients with ocular viral infections.